cancer predisposition genes; early cancers; multiple primary cancers; single nucleotide variants; whole exome sequencing; Oncology; Cancer Research
Abstract :
[en] Regarding inherited cancer predisposition, single gene carriers of pathogenic variants (PVs) have been extensively reported on in the literature, whereas the oligogenic coinheritance of heterozygous PVs in cancer-related genes is a poorly studied event. Currently, due to the increased number of cancer survivors, the probability of patients presenting with multiple primary cancers (MPCs) is higher. The present study included patients with MPCs aged ≤45 years without known PVs in common cancer predisposition genes. This study used whole exome sequencing (WES) of germline and tumoral DNA, chromosomal microarray analysis (CMA) of germline DNA (patients 1-7, 9 and 10), and a karyotype test of patient 8 to detect variants associated with the disease. The 10 patients included in the study presented a mean of 3 cancers per patient. CMA showed two microduplications and one microdeletion, while WES of the germline DNA identified 1-3 single nucleotide variants of potential interest to the disease in each patient and two additional copy number variants. Most of the identified variants were classified as variants of uncertain significance. The mapping of the germline variants into their pathways showed a possible additive effect of these as the cause of the cancer. A total of 12 somatic samples from 5 patients were available for sequencing. All of the germline variants were also present in the somatic samples, while no second hits were identified in the same genes. The sequencing of patients with early cancers, family history and multiple tumors is already a standard of care. However, growing evidence has suggested that the assessment of patients should not stop at the identification of one PV in a cancer predisposition gene.
Disciplines :
Genetics & genetic processes
Author, co-author :
Freire, Maria Valeria; Department of Human Genetics, GIGA Research Center-University of Liège and CHU Liège, 4000 Liège, Belgium
Martin, Marie ; Université de Liège - ULiège > Département des sciences cliniques
Fasquelle, Corinne ; Centre Hospitalier Universitaire de Liège - CHU > > Service de génétique
HELOU, Laura ; Centre Hospitalier Universitaire de Liège - CHU > > Service de génétique
Durkin, Keith ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques
Artesi, Maria ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Génétique humaine
Lumaka, Aimé; Department of Human Genetics, GIGA Research Center-University of Liège and CHU Liège, 4000 Liège, Belgium ; Department of Human Genetics, CHU Liège, 4000 Liège, Belgium
LEROI, Natacha ; Centre Hospitalier Universitaire de Liège - CHU > > Service de génétique
Segers, Karin; Department of Human Genetics, CHU Liège, 4000 Liège, Belgium
DEBERG, Michelle ; Centre Hospitalier Universitaire de Liège - CHU > > Service de génétique
Gatot, Jean-Stéphane ; Université de Liège - ULiège > Département des sciences cliniques
Habran, Lionel ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques
Palmeira, Leonor ; Université de Liège - ULiège > Département des sciences cliniques
Josse, Claire ; Université de Liège - ULiège > GIGA > GIGA Cancer - Human Genetics
Bours, Vincent ; Université de Liège - ULiège > GIGA > GIGA Cancer - Human Genetics
Genetic evaluation of patients with multiple primary cancers.
Publication date :
January 2025
Journal title :
Oncology Letters
ISSN :
1792-1074
eISSN :
1792-1082
Publisher :
Spandidos Publications, Greece
Volume :
29
Issue :
1
Pages :
4
Peer reviewed :
Peer Reviewed verified by ORBi
Funding text :
This work was supported by Televie (grant no. 7451419F); CHU Liege (grant no. 981481200); Region Wallonne (grant no. 1710180).The CHU Li\u00E8ge is a member of the GENTURIS (GENetic TUmor RISk) European Reference Network. This work was supported by Televie (grant no. 7451419F); CHU Liege (grant no. 981481200); Region Wallonne (grant no. 1710180).
Dickie L, Johnson CH, Adams S and Serban N (eds): Solid tumor rules. Effective with Cases Diagnosed 1/1/2018 and Forward. National Cancer, Rockville, MD, 2021. https://seer.cancer.gov/tools/solidtumor/STM.pdf. Accessed March 9, 2023.
Report WG: International rules for multiple primary cancers (ICD-0 third edition). Eur J Cancer Prev 14: 307-308, 2005. ONCOLOGY LETTERS 29: 4, 2025 9
American Cancer Society: Cancer Facts & Figures 2009. American Cancer Society, Atlanta, GA, 2019. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2009.html. Accessed April 6, 2023.
Cybulski C, Nazarali S and Narod SA: Multiple primary cancers as a guide to heritability. Int J Cancer 135: 1756-1763, 2014.
Chan GHJ, Ong PY, Low JJH, Kong HL, Ow SGW, Tan DSP, Lim YW, Lim SE and Lee SC: Clinical genetic testing outcome with multi-gene panel in Asian patients with multiple primary cancers. Oncotarget 9: 30649-30660, 2018.
Harvengt J, Lumaka A, Fasquelle C, Caberg JH, Mastouri M, Janssen A, Palmeira L and Bours V: HIDEA syndrome: A new case report highlighting similarities with ROHHAD syndrome. Front Genet 14: 1137767, 2023.
Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, et al: Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. Genet Med 17: 405-424, 2015.
Backenroth D, Homsy J, Murillo LR, Glessner J, Lin E, Brueckner M, Lifton R, Goldmuntz E, Chung WK and Shen Y: CANOES: Detecting rare copy number variants from whole exome sequencing data. Nucleic Acids Res 42: e97, 2014.
Riggs ER, Andersen EF, Cherry AM, Kantarci S, Kearney H, Patel A, Raca G, Ritter DI, South ST, Thorland EC, et al: Technical standards for the interpretation and reporting of constitutional copy number variants: A joint consensus recommendation of the American college of medical genetics and genomics (ACMG) and the clinical genome resource (ClinGen). Genet Med 22: 245-257, 2020.
Li MM, Datto M, Duncavage EJ, Kulkarni S, Lindeman NI, Roy S, Tsimberidou AM, Vnencak-Jones CL, Wolff DJ, Younes A and Nikiforova MN: Standards and guidelines for the interpretation and reporting of sequence variants in cancer. J Mol Diagn 19: 4-23, 2017.
Blokzijl F, Janssen R, van Boxtel R and Cuppen E: MutationalPatterns: Comprehensive genome-wide analysis of mutational processes. Genome Med 10: 33, 2018.
Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Børresen-Dale AL, et al: Signatures of mutational processes in human cancer. Nature 500: 415-421, 2013.
Nielsen M, Joerink-van de Beld MC, Jones N, Vogt S, Tops CM, Vasen HFA, Sampson JR, Aretz S and Hes FJ: Analysis of MUTYH genotypes and colorectal phenotypes in patients with MUTYH-associated polyposis. Gastroenterology 136: 471-476, 2009.
Barreiro RAS, Sabbaga J, Rossi BM, Achatz MIW, Bettoni F, Camargo AA, Asprino PF and Galante PAF: Monoallelic deleterious MUTYH germline variants as a driver for tumorigenesis. J Pathol 256: 214-222, 2022.
Abou Tayoun AN, Pesaran T, DiStefano MT, Oza A, Rehm HL, Biesecker LG and Harrison SM; ClinGen Sequence Variant Interpretation Working Group (ClinGen SVI): Recommendations for interpreting the loss of function PVS1 ACMG/AMP variant criterion. Hum Mutat 39: 1517-1524, 2018.
Whitworth J, Smith PS, Martin JE, West H, Luchetti A, Rodger F, Clark G, Carss K, Stephens J, Stirrups K, et al: Comprehensive cancer-predisposition gene testing in an adult multiple primary tumor series shows a broad range of deleterious variants and atypical tumor phenotypes. Am J Hum Genet 103: 3-18, 2018.
Liu YL, Cadoo KA, Mukherjee S, Khurram A, Tkachuk K, Kemel Y, Maio A, Belhadj S, Carlo MI, Latham A, et al: Multiple primary cancers in patients undergoing tumor-normal sequencing define novel associations. Cancer Epidemiol Biomarkers Prev 31: 362-371, 2022.
McGuigan A, Whitworth J, Andreou A, Hearn T, Tischkowitz M and Maher ER: Multilocus inherited neoplasia allele syndrome (MINAS): An update. Eur J Hum Genet 30: 265-270, 2022.
Aston CE, Ralph DA, Lalo DP, Manjeshwar S, Gramling BA, DeFreese DC, West AD, Branam DE, Thompson LF, Craft MA, et al: Oligogenic combinations associated with breast cancer risk in women under 53 years of age. Hum Genet 116: 208-221, 2005.
Renieri A, Mencarelli MA, Cetta F, Baldassarri M, Mari F, Furini S, Piu P, Ariani F, Dragani TA and Frullanti E: Oligogenic germline mutations identified in early non-smokers lung adenocarcinoma patients. Lung Cancer 85: 168-1674, 2014.
Weischer M, Heerfordt IM, Bojesen SE, Eigentler T, Garbe C, Röcken M, Hölmich LR, Schmidt H, Klyver H, Bastholt L and Nordestgaard BG: CHEK2*1100delC and risk of malignant melanoma: Danish and German studies and meta-analysis. J Invest Dermatol 132: 299-303, 2012.
AlDubayan SH, Pyle LC, Gamulin M, Kulis T, Moore ND, Taylor-Weiner A, Hamid AA, Reardon B, Wubbenhorst B, Godse R, et al: Association of inherited pathogenic variants in checkpoint kinase 2 (CHEK2) with susceptibility to testicular germ cell tumors. JAMA Oncol 5: 514-522, 2019.
Stolarova L, Kleiblova P, Janatova M, Soukupova J, Zemankova P, Macurek L and Kleibl Z: CHEK2 germline variants in cancer predisposition: Stalemate rather than checkmate. Cells 9: 2675, 2020.
Xu J, Zheng SL, Komiya A, Mychaleckyj JC, Isaacs SD, Hu JJ, Sterling D, Lange EM, Hawkins GA, Turner A, et al: Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet 32: 321-325, 2002.
Orloff M, Peterson C, He X, Ganapathi S, Heald B, Yang YR, Bebek G, Romigh T, Song JH, Wu W, et al: Germline mutations in MSR1, ASCC1, and CTHRC1 in patients with barrett esophagus and esophageal adenocarcinoma. JAMA 306: 410-419, 2011.
Wen WX, Soo JS, Kwan PY, Hong E, Khang TF, Mariapun S, Lee CS, Hasan SN, Rajadurai P, Yip CH, et al: Germline APOBEC3B deletion is associated with breast cancer risk in an Asian multi-ethnic cohort and with immune cell presentation. Breast Cancer Res 18: 56, 2016.
Freire Chadrina M, Martin M and Segers K: Sepulchre. Coinheritance of pathogenic variants in ATM and BRCA2 in families with multiple cancers: A case series (Internet). 2022 (cited 2023 Feb 23).
Vietri MT, Caliendo G, D'Elia G, Resse M, Casamassimi A, Minucci PB, Dello Ioio C, Cioffi M and Molinari AM: Five Italian families with two mutations in BRCA genes. Genes (Basel) 11: 1451, 2020.
Huang W, Bian J, Qian X, Shao L, Li H, Zhang L and Wang L: Case report: Coinheritance of germline mutations in APC and BRCA1 in colorectal cancer. Front Oncol 11: 658389, 2021.
Borde J, Ernst C, Wappenschmidt B, Niederacher D, Weber-Lassalle K, Schmidt G, Hauke J, Quante AS, Weber-Lassalle N, Horváth J, et al: Performance of breast cancer polygenic risk scores in 760 female CHEK2 germline mutation carriers. J Natl Cancer Inst 113: 893-899, 2020.
Potorac I, Laterre M, Malaise O, Nechifor V, Fasquelle C, Colleye O, Detrembleur N, Verdin H, Symoens S, De Baere E, et al : The role of MCM9 in the etiology of sertoli cell-only syndrome and premature ovarian insufficiency. J Clin Med 12: 990, 2023.
